Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19.

Razonable, Raymund R; Ganesh, Ravindra; Bierle, Dennis M

Razonable, Raymund R; Ganesh, Ravindra; Bierle, Dennis M.

Razonable RR; Division of Infectious Diseases, Mayo Clinic, Rochester, MN. Electronic address: Razonable.raymund@mayo.edu.
Ganesh R; Division of General Internal Medicine, Mayo Clinic, Rochester, MN.
Bierle DM; Division of General Internal Medicine, Mayo Clinic, Rochester, MN.

Mayo Clin Proc ; 97(1): 26-30, 2022 01.

Article in English | MEDLINE | ID: covidwho-1587020

Subject(s)

Antibodies, Monoclonal/therapeutic use; COVID-19/therapy; Critical Pathways/organization & administration; Severity of Illness Index; Spike Glycoprotein, Coronavirus/immunology; Antiviral Agents/therapeutic use; COVID-19/immunology; Humans; SARS-CoV-2/immunology

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Severity of Illness Index / Critical Pathways / Spike Glycoprotein, Coronavirus / COVID-19 / Antibodies, Monoclonal Type of study: Prognostic study Limits: Humans Language: English Journal: Mayo Clin Proc Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google